This content is from: Portfolio A Jim Simons Market Mystery — Solved? A secretive investment fund backed by the legendary quant displays a penchant for biotech stocks. There’s a good reason for that. By Richard Teitelbaum February 07, 2023
This content is from: Premium These Biopharma Funds Made a Comeback Last Year While some funds posted huge losses in 2022, several others managed to turn sharp losses into profitability. By Stephen Taub January 19, 2023
This content is from: Premium Biopharma Funds Regain Some Health At least one fund is in the black, and several others moved closer to breakeven in October. By Stephen Taub November 17, 2022
This content is from: Premium VC Financing Is Down, But Not Out At least four hedge funds participated in three of the largest private financings in October, with biotech leading the way. By Stephen Taub November 03, 2022
Sponsored Advent, AlpInvest Offload €365M Nucletron U.S. private equity firm Advent International and Dutch fund of funds investor AlpInvest have sold their holdings in oncology therapy business Nucletron for €365 million. June 23, 2011
This content is from: Premium Healthcare Hedge Funds Shine as This Year’s Winning Strategy Managers are plowing money into oncology and genomics-oriented companies — and reaping rewards. By Michelle Celarier October 08, 2018
